To get any sort of meaningful answer you need to apply more specifics
(iii) If a generic Part D rebatable drug or biosimilar that is currently in shortage experiences a severe supply chain disruption, CMS will reduce the rebate amount as described in paragraph (b)(1) of this section, and will not grant a reduction under 428.301 during that applicable period
When it is thought of as never being a possibility, the chances of being diagnosed in a later stage significantly increases
Meanwhile, their costs increased
(2) Identification of the Payment Amount Benchmark Period Consistent with section 1860D-14B(g)(3) of the Act and as described in sections 40.2.2 and 40.3 of the revised Medicare Part D Drug Inflation Rebate Guidance, CMS proposes in 428.202(c)(1) that for a drug first approved or licensed by the FDA on or before October 1, 2021, the payment amount benchmark period is the period beginning on January 1, 2021 and ending on September 30, 2021
